Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Six Weeks Too Late? Praxbind Gets 2017 Medicare Boost But Not AndexXa

Executive Summary

User fee date for Portola's anticoagulant reversal agent is near, but not soon enough for Medicare's new technology payments in 2017 – while Boehringer's Praxbind gets in in time; BTG's Vistogard also gains the extra payments.

You may also be interested in...



Keeping Track: Janssen Gets A Breakthrough Therapy Status, FDA Awards Two Orphan Drug Designations, Portola Lands A CRL

The latest drug development news and highlights from our FDA Performance Tracker.

Key Clinical Data And Drug Approvals Expected In 2H 2016

As July is already upon us, Scrip takes a look at some of the more interesting clinical trial read-outs and drug approvals expected clinical trials due to report in the second half of the year.

Medicare Add-On Payments For Praxbind, Andexanet Under Consideration

Although few drugs have ever gotten the new technology designation, the two antidotes for excessive bleeding caused by anticoagulant treatments seem to have a good chance of being awarded added payments by CMS.

Topics

Related Companies

UsernamePublicRestriction

Register

PS118919

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel